Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: Role of the Conditioning Regimen and the Type of Transplantation

Changes in plasmatic levels of vWF and ADAMTS-13 activity. Graphs represent changes in VWF (●) and ADAMTS-13 activity (○) levels in plasma samples from recipients of autologous HSCT with BEAM and MLF conditioning treatments, and of allogeneic HSCT with Cy/TBI and Flu/MLF treatments, as indicated. Levels were determined at the different time points of the study: before starting conditioning regimen (Pre), immediately before the infusion of the hematopoietic stem cells (day 0), and days 7, 14, and 21 after the HSCT. Data are expressed as ratios with respect to the Pre value and correspond to mean ± SEM (∗P < .05; n = 6, 5, 5, and 8 for the BEAM, MLF, Cy/TBI, and Flu/MLF, respectively).

Changes in the levels of sVCAM-1 and sICAM-1 in patients without TRC from the autologous and allogeneic groups. Graphs represent changes in soluble VCAM-1 and ICAM-1 levels in plasma from recipients of autologous HSCT with BEAM (●) and MLF (○) conditioning treatments, and of allogeneic HSCT with Cy/TBI (▴) and Flu/MLF (Δ) treatments. Levels were determined at the different time points of the study: before starting conditioning regimen (Pre), immediately before the infusion of the hematopoietic stem cells (day 0), and days 7, 14, and 21 after the HSCT. Data are expressed as ratios with respect to the Pre value and correspond to mean ± SEM (∗P < 0.05; n = 6, 5, 5, and 8 for the BEAM, MLF, Cy/TBI, and Flu/MLF, respectively).

Levels of plasmatic soluble TNF receptor I in patients without TRC. Graphs representing changes in soluble TNFRI levels in plasma from recipients of autologous HSCT with BEAM (●) and MLF (○) conditioning treatments, and of allogeneic HSCT with Cy/TBI (▴) and Flu/MLF (▵) treatments. Levels were determined at the different time points of the study: before starting conditioning regimen (Pre), immediately before the infusion of the hematopoietic stem cells (day 0), and days 7, 14, and 21 after the HSCT. Data are expressed as ratios with respect to the Pre value and correspond to mean ± SEM (∗P < .05; n = 6, 5, 5, and 8 for the BEAM, MLF, Cy/TBI and Flu/MLF, respectively).

Kinetics of VWF in patients with TRC versus those without complications. Graphs show VWF levels in recipients of autologous HSCT (a) and allogeneic HSCT (b and c) with (•) and without (o) transplant related complications. ES = engraftment syndrome (n =11); GVHD = graft-versus-host disease (n = 7); VOD = venooclusive disease (n = 2). Data are expressed as absolute values in % (mean ± SEM) (∗P < .05; for days 7, 14, and 21 versus day Pre).